These preclinical studies provide evidence that MET amplification can arise as a known mechanism of resistance in EGFR-mutated NSCLC treated with EGFR TKIs, supporting the need for combination therapies targeting both EGFR and MET pathways to improve treatment outcomes. The gene discussed is MET; the disease is non-small cell lung carcinoma.